Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Targeted protein degradation (TPD) is an emerging therapeutic strategy to control protein levels, addressing previously undruggable targets.
• Proteolysis TArgeting Chimeras (PROTACs) represent a powerful TPD approach, offering distinct advantages over direct inhibition.
• The application of PROTAC technology to integral membrane proteins (IMPs) remains underdeveloped, with limited clinical progression.

Purpose of the Study:

• To review the current limitations hindering the use of PROTACs against integral membrane proteins (IMPs).
• To discuss potential reasons for the slow progress in targeting IMPs with PROTACs.
• To present novel tools and strategies designed to overcome these challenges and facilitate IMP degradation via PROTACs.

Main Methods:

• Literature review of existing PROTAC technology and its application to IMPs.
• Analysis of factors contributing to the difficulty in degrading IMPs using PROTACs.
• Identification and description of newly developed tools and methodologies for targeting IMPs with PROTACs.

Main Results:

• Limited clinical success of PROTACs targeting membrane proteins suggests significant hurdles.
• Several factors, including protein localization and cellular environment, pose challenges for PROTAC efficacy against IMPs.
• Emerging tools and strategies show promise in enhancing PROTAC-mediated degradation of IMPs.

Conclusions:

• Despite challenges, PROTAC technology holds significant potential for targeting IMPs.
• Advancements in tool development are crucial for expanding the therapeutic application of PROTACs to the 'undruggable' IMP proteome.
• Further research and innovation are needed to fully realize the therapeutic benefits of PROTACs for IMP-related diseases.